Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 58Ovarian Neoplasms 7Neoplasm Metastasis 7Endometrial Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Advanced Breast Cancer 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Neoplasms by Site 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2Advanced Solid Tumors 2Advanced Solid Tumor 2Unilateral Breast Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1HR+ Breast Cancer 1

Interventions

ribociclib 1palbociclib 1giredestrant 1abemaciclib 1Gonadotropin-Releasing Hormone 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer × Fulvestrant × Clear all
NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Recruiting
1,050 enrolled
Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡